Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-ggqkh Total loading time: 0 Render date: 2025-05-05T23:56:07.268Z Has data issue: false hasContentIssue false

Chapter 29 - Respiratory System: Pharmacology

Published online by Cambridge University Press:  21 February 2025

By
Kyle James Riley  and
Daniel Katz
Edited by
Dharti Patel ,
Sang J. Kim ,
Himani V. Bhatt  and
Alopi M. Patel
Dharti Patel
Affiliation:
Mount Sinai West and Morningside Hospitals, New York
Sang J. Kim
Affiliation:
Hospital for Special Surgery, New York
Himani V. Bhatt
Affiliation:
Mount Sinai West and Morningside Hospitals, New York
Alopi M. Patel
Affiliation:
Rutgers Robert Wood Johnson Medical School, New Jersey
Get access

Summary

Lower respiratory tract disorders, which include pulmonary disorders like asthma and chronic obstructive pulmonary disease (COPD), are prevalent. This chapter discusses the pharmacology of some of the important classes of drugs used to treat these conditions. Bronchodilators relax smooth muscles and expand airways. Beta-2 agonists and anticholinergics are the two most commonly used bronchodilators used for this purpose. They are available in both short-acting and long-acting formulations. Short-acting (e.g. albuterol) are used as required for sudden episodes of breathlessness, while long-acting may be added if symptoms are not controlled or progress. Bronchodilators help to improve a patient’s overall quality of life through improved lung function, a decrease in symptoms, and improved exercise capacity. Corticosteroids, leukotriene modifiers, mast cell stabilizers, and Immunoglobulin E (IgE) blockers are classes of anti-inflammatory medications that have been shown to be effective treatments in controlling asthma symptoms and attacks. Research and experience have shown that a combination of these medications may be required. This can particularly be true for patients with intermediate and severe symptoms where a single medication has been inadequate in controlling/preventing recurrent symptoms.

Keywords

BronchodilatorsBeta-2 AgonistsAnticholinergicsCorticosteroidsLeukotriene ModifiersMast Cell StabilizersImmunoglobulin E (IgE) Blockers
Type
Chapter
Information
BASIC Essentials
A Comprehensive Review for the Anesthesiology BASIC Exam
 , pp. 158 - 160
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

CDC/National Center for Health Statistics. Asthma. 2017. Available at: www.cdc.gov/nchs/fastats/asthma.htm (accessed February 28, 2017).Google Scholar
National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. Chronic obstructive pulmonary disease (COPD). 2016. Available at: www.cdc.gov/copd/index.html (accessed February 28, 2017).Google Scholar
National Heart, Lung, and Blood Institute, National Institutes of Health. Asthma Care Quick Reference. Guidelines from the National Asthma Education and Prevention Program. Expert Panel Report 2. 2012. Available at: www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf (accessed February 27, 2017).Google Scholar
Rabe, KF, Hurd, S, Anzueto, A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532–555.CrossRefGoogle ScholarPubMed
Ram, FS, Sestini, P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003;58(7):580–584.CrossRefGoogle ScholarPubMed
Buhl, R, Maltais, F, Abrahams, R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45(4):969–979.CrossRefGoogle ScholarPubMed
Cooper, CB, Tashkin, DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005;330(7492):640–644.CrossRefGoogle ScholarPubMed
Pfitzer, G. Invited review: regulation of myosin phosphorylation in smooth muscle. J Appl Physiol (1985) 2001;91(1):497–503.CrossRefGoogle ScholarPubMed
Bai, Y, Sanderson, MJ. Airway smooth muscle relaxation results from a reduction in the frequency of Ca2+ oscillations induced by a cAMP-mediated inhibition of the IP3 receptor. Respir Res 2006;7:34.CrossRefGoogle ScholarPubMed
Perez-Zoghbi, JF, Karner, C, Ito, S, et al. Ion channel regulation of intracellular calcium and airway smooth muscle function. Pulm Pharmacol Ther 2009;22(5):388–397.CrossRefGoogle ScholarPubMed
Delmotte, P, Sanderson, MJ. Effects of albuterol isomers on the contraction and Ca2+ signaling of small airways in mouse lung slices. Am J Respir Cell Mol Biol 2008;38(5):524–531.CrossRefGoogle ScholarPubMed
Rhoden, KJ, Meldrum, LA, Barnes, PJ. Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol (1985) 1988;65(2):700–705.CrossRefGoogle Scholar
Scola, AM, Loxham, M, Charlton, SJ, Peachell, PT. The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 2009;158(1):267–276.CrossRefGoogle ScholarPubMed
Gosens, R, Zaagsma, J, Meurs, H, Halayko, AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006;7:73.CrossRefGoogle ScholarPubMed
Penn, RB, Benovic, JL. Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 2008;5(1):47–57.CrossRefGoogle ScholarPubMed
Jude, JA, Wylam, ME, Walseth, TF, Kannan, MS. Calcium signaling in airway smooth muscle. Proc Am Thorac Soc 2008;5(1):15–22.CrossRefGoogle ScholarPubMed
Barnes, PJ, Chung, KF, Page, CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;50(4):515–596.CrossRefGoogle ScholarPubMed
Busse, WW, Lemanske, RFJ. Asthma. N Engl J Med 2001;344(5):350–362.CrossRefGoogle ScholarPubMed
Barnes, PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148(3):245–254.CrossRefGoogle ScholarPubMed
Mak, JC, Hisada, T, Salmon, M, Barnes, PJ, Chung, KF. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 2002;135(4):987–996.CrossRefGoogle ScholarPubMed
Eickelberg, O, Roth, M, Lorx, R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274(2):1005–1010.CrossRefGoogle ScholarPubMed
Radmark, O, Werz, O, Steinhilber, D, Samuelsson, B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32(7):332–341.CrossRefGoogle ScholarPubMed
Peters-Golden, M, Henderson, WR Jr. Leukotrienes. N Engl J Med 2007;357(18):1841–1854.CrossRefGoogle ScholarPubMed
Finn, DF, Walsh, JJ. Twenty-first century mast cell stabilizers. Br J Pharmacol 2013;170(1):23–37.CrossRefGoogle ScholarPubMed
Gould, HJ, Sutton, BJ, Beavil, AJ, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003;21:579–628.CrossRefGoogle ScholarPubMed
Fahy, JV, Fleming, HE, Wong, HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155(6):1828–1834.CrossRefGoogle ScholarPubMed
Parikh, N, Chakraborti, A. Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions. Curr Med Chem 2016;23(2):129–141.CrossRefGoogle ScholarPubMed
Li, H, Zuo, J, Tang, W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 2018;9:1048.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×